BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.02 -1.42 (2.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.44 | 52 Week High | $108.96 | |||
| Open | $53.06 | 52 Week Low | $62.12 | |||
| Day High | $56.33 | P/E | N/A | |||
| Day Low | $52.50 | EPS | $-1.27 | |||
| Volume | 2,986,872 | |||||
